n (%) or mean ± SD | |
---|---|
Male gender | 18 (78.3) |
Age (years-old) | 48.8 ± 17.8 (21–82) |
Charlson’s comorbidity index | 0.78 ± 1.98 (0–8) |
Primary admission | 18 (78.3) |
APACHE II | 19.4 ± 5.5 (10–32) |
SAPS II | 41.3 ± 12.2 (20–78) |
SOFA | 6.9 ± 3.2 (2–10) |
Shock index | 0.82 ± 0.25 (0.31–1.4) |
Abbreviated Injury Scale | 15.4 ± 4.9 (10–25) |
Injury Severity Score | 47.9 ± 18.5 (27–75) |
Revised Trauma Score | 5.9 ± 1.3 (3.6–7.6) |
Invasive ventilation | 23 (100) |
Renal replacement therapy | 0 (0) |
Amines perfusion | 16 (69.6) |
Erythrocytes transfusion | 14 (60.9) |
Nutritional support | |
Enteral/Parenteral | 23 (100)/1 (4.3) |
Glutamine supplementationa | 1 (4.3) |
Surgical proceduresb | 14 (65.2) |
Mortality rate | |
ICU/Hospital/Global | 4 (17.4)/6 (26.1)/10 (43.5) |
Health care-associated infections rate | 20 (87) |
Ventilation support (days) | 12.7 ± 7.8 (2–27) |
Length of stay (days) | |
ICU/Hospital (days) | 13.9 ± 9.1 (3–52)/29.4 ± 21.9 (5–95) |
Follow-up (months) | 7.4 ± 3.1 (2.3–12.2) |
Actuarial survival (days) | 229.2 ± 32.9 (95 % CI 164.7–293.8) |
Karnofsky’s index | 69 ± 17.3 (40–90) |